Invasive Pulmonary Aspergillosis (IPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Invasive pulmonary aspergillosis (IPA) is a severe fungal infection associated with a high mortality rate. The incidence of IPA is on the rise, primarily due to the increasing number of patients undergoing transplants, receiving chemotherapy, and undergoing immunosuppressive therapy. Invasive pulmonary aspergillosis typically manifests in two distinct scenarios:

1.       The classic form of invasive pulmonary aspergillosis occurs as primary pneumonia in patients with profound immunosuppression, such as prolonged neutropenia. This particular presentation has been recognized for many years.

2.       Another common scenario is secondary nosocomial pneumonia, which affects patients admitted to the ICU for other reasons, like ARDS caused by influenza. It is a challenging diagnosis because critically ill patients with superinfections of aspergillus are not usually profoundly immunosuppressed. This superinfection can closely resemble bacterial pneumonia or ARDS and may be overshadowed by the patient's other medical issues.

The diagnosis of IPA is complicated due to the non-specific nature of its symptoms. The mainstay of therapy for IPA is Voriconazole. This condition primarily affects severely immunocompromised individuals, including those with prolonged neutropenia resulting from chemotherapy, immunosuppressive therapy, post-hematopoietic stem cell transplant (SCT), or solid organ transplant. When evaluating a child with a cystic or cavitary lung lesion, the list of potential causes is extensive and includes both congenital and acquired lung abnormalities. Congenital cystic lesions include lobar emphysema, cystic adenomatoid malformations, pleuropulmonary blastoma, bronchogenic cysts, and pulmonary sequestration. Acquired lung lesions are categorized as infectious, neoplastic, or stemming from miscellaneous causes. Bacterial and fungal infections predominate among the common infectious causes, while parasitic infestations like paragonimiasis and hydatidosis are rare outside of endemic regions. Pulmonary cysts or pneumatoceles are most commonly associated with organisms such as Staphylococcus, Pseudomonas, Klebsiella, and anaerobes. Lung abscesses can be caused by gram-negative bacteria, anaerobes, and occasionally Staphylococcus.

·       The overall one-year mortality rate for IPA is 32%. Specifically, patients with COVID-19 in the ICU have the highest one-year mortality rate, followed by those with acute myeloid leukemia and aplastic anemia, with mortality rates of 54%, 50%, and 39%, respectively.

 

Thelansis’s “Invasive Pulmonary Aspergillosis (IPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Pulmonary Aspergillosis (IPA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Invasive Pulmonary Aspergillosis (IPA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Invasive Pulmonary Aspergillosis (IPA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Invasive Pulmonary Aspergillosis (IPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Invasive Pulmonary Aspergillosis (IPA), Invasive Pulmonary Aspergillosis (IPA) market outlook, Invasive Pulmonary Aspergillosis (IPA) competitive landscape, Invasive Pulmonary Aspergillosis (IPA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)